United States of America tariff update
| Stock | Somnomed Ltd (SOM.ASX) |
|---|---|
| Release Time | 7 Apr 2025, 3:22 p.m. |
| Price Sensitive | Yes |
SomnoMed provides update on US tariffs
- SomnoMed assessing impact of new US tariffs on imports
- Company plans to absorb tariff costs in the immediate term
- Reiterates previous FY25 guidance of $105M revenue and $7-9M EBITDA
SomnoMed Limited, the leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), has provided an update in response to the reciprocal tariffs announced by the United States of America (USA) on 2 April 2025. The company has conducted a preliminary assessment of the potential impact of these new tariffs on goods imported into the USA, noting that the Philippines is the primary manufacturing location for SomnoMed's products. Given the uncertain and evolving impact of the USA tariff policies, SomnoMed will continue to evaluate how these tariffs affect its operations and adjust its response accordingly. In the immediate term, the Company plans to absorb the costs associated with the tariff changes to ensure patients have uninterrupted access to care. SomnoMed reiterates its previous FY25 guidance of approximately $105 million revenue and EBITDA of between $7 million to $9 million.
SomnoMed reiterates its previous FY25 guidance of approximately $105 million revenue and EBITDA of between $7 million to $9 million.